Citius Pharmaceuticals, Inc.
CTXR
$0.85
$0.000.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.18% | -4.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.99% | -21.96% | |||
| Operating Income | 3.99% | 21.96% | |||
| Income Before Tax | 5.15% | 20.52% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | 5.00% | 20.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 89.47% | -30.42% | |||
| Net Income | 9.45% | 19.48% | |||
| EBIT | 3.99% | 21.96% | |||
| EBITDA | 3.99% | 21.96% | |||
| EPS Basic | 42.05% | 37.22% | |||
| Normalized Basic EPS | 44.15% | 37.32% | |||
| EPS Diluted | 42.05% | 37.22% | |||
| Normalized Diluted EPS | 44.15% | 37.32% | |||
| Average Basic Shares Outstanding | 56.26% | 28.27% | |||
| Average Diluted Shares Outstanding | 56.26% | 28.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||